Notably, erythropoietin-stimulating agents were efficacious in improving anemia in 59 anemic MF patients treated with ruxolitinib, with an anemia response rate of 54% and minor improvements in Hb levels in an additional 15% of patients, and no thrombotic events reported [32]. This evidence concerns the gene EPO and anemia.